Three independent discounted-cash-flow-style models value Regeneron Pharmaceuticals Inc every trading day. 0 of 3 currently price REGN above its market price.
| Free Cash Flow model | $116.14 |
| Excess Profit model | $307.09 |
| Residual Earnings model | $352.66 |
| Dividend Discount model | $46.12 |
| Piotroski F-Score | 5 / 9 |
| Return on invested capital | +7.8% |
| Net debt / EBITDA | 0.5× |
| Gross margin | +85.4% |
| Revenue CAGR | +5.6% |
| Cash conversion | 1.1× |
| Dividend yield | +0.5% |
| Buyback yield | +3.1% |
These are StockKitty's default assumptions. In the app, the models recompute live as you adjust growth, discount rates, and margins — and the AI explains the bull case, bear case, and quality picture.
Open REGN in StockKitty